|Videos|June 19, 2023
CARD Trial: Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
Author(s)Alicia K. Morgans, MD, MPH
Focused discussion on the CARD trial, which utilized cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5